Fig. 4From: Prediction model for hyperprogressive disease in patients with advanced solid tumors received immune-checkpoint inhibitors: a pan-cancer studyDifferential analysis of clinical features between HPD and non-HPD groups. A. Differential analysis of clinical characteristics between HPD and non-HPD groups. B. Differential analysis of CA-199, Hbg, BMI, Albumin, and ALP between HPD and non-HPD groups (p<0.001 ***, p<0.01 **, p<0.05 *)Back to article page